According to an alarming report in the September issue of the journal Lancet Oncology, the number of new cancer cases worldwide expect to reach 27 million / year in 2030.The authors of the document requires a comprehensive effort to better control costs and human suffering by highlighting the “real value of new technologies.” One of the “new” technology, which is under investigation is the use of bitter melon (Momordica charantia) common malignancies such as prostate cancer. In June 2010, described the scientific evaluation of this pie, functional foods that have “anti-tumor activity” and “not-to-low side effects in animals as in humans.” Later, in 2010 and continued until 2011, preliminary evidence appeared to indicate that bitter melon extract (BME) to successfully intervene in progression of prostate cancer in animal models and in vitro. But why are so excited about several studies that have not even finished in humans?
The reason for my optimism is due to seemingly independent studies that have examined the potential of bitter melon in the management of diabetes in animals and humans alike. For example, the publication appears in the March 2011 issue of the Journal of Ethnopharmacology, that the daily dose of 2,000 mg BME effectively lowers blood glucose levels and fruktosaminkoncentration in group 2 diabetes type. Meanwhile, a survey from August 2011 to diabetic rats also found that BME “strong decrease (blood) glucose levels.” In fact, the excitement around bitter melon so large that nutritionists are desperately trying to find ways to more palatable to encourage greater consumption of the population as a whole. You hope that they manage their objectives and that further research continue to be published to promote the use of bitter melon in the fight against cancer and other places.